Optimal care of lupus nephritis patients should include the treatment of proteinuria and hypertension, other measures to delay the progression of chronic kidney disease, the vigorous management of cardiovascular risk factors and finally, the treatment of advanced chronic kidney disease and its consequences. These topics are briefly reviewed in the present paper, with particular emphasis on the recent progresses in antiproteinuric treatment.
Bjornadal L , Yin L , Granath F , Klareskog L , Ekbom A.Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95 . Journal of Rheumatology2004; 31: 713-719 .
2.
Remuzzi G , Bertani T.Pathophysiology of progressive nephropathies . New England Journal of Medicine1998; 339: 1448-1456 .
3.
Taal MW , Brenner BM.Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists . Kidney International2000; 57: 1803-1817 .
4.
Lewis EJ , Hunsicker LG , Bain RP , Rohde RD.The effect of angiotensin-converting enzyme-inhibition on diabetic nephropathy . New England Journal of Medicine1993; 329: 1456-1462 .
5.
Maschio G , Alberti D , Janin Get al.Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency . New England Journal of Medicine1996; 334: 939-945 .
6.
Ruggenenti P , Perna A , Mosconi Let al.Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy . Lancet1997; 349: 1857-1863 .
7.
Ruggenenti P , Perna A , Gherardi Get al.Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial . Lancet1998; 352: 1252-1256 .
8.
Ruggenenti P , Perna A , Gherardi Get al.Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria . Lancet1999; 354: 359-364 .
9.
Lewis EJ , Hunsicker LG , Clarke WRet al.Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes . New England Journal of Medicine2001; 345: 851-860 .
10.
Brenner BM , Cooper ME , de Zeeuw Det al.Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy . New England Journal of Medicine2001; 345: 861-869 .
11.
Jafar TH , Schmid CH , Landa Met al.Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease - a meta-analysis of patient-level data . Annals of Internal Medicine2001; 135: 73-87 .
12.
Campbell R , Sangalli F , Perticucci Eet al.Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies . Kidney International2003; 63: 1094-1103 .
13.
Jacobsen PK , Andersen S , Rossing K , Jensen BR , Parving HH.Dual blockade of the renin angiotensin system versus maximal recommended dose of ACE-inhibition in Type 1 patients with diabetic nephropathy . Diabetologia2003; 46: A339-A339 .
14.
Nakao N , Yoshimura A , Morita Het al.Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial . Lancet2003; 361: 1230-1230 .
15.
Ruggenenti P , Perna A , Remuzzi G.Retarding progression of chronic renal disease: the neglected issue of residual proteinuria . Kidney International2003; 63: 2254-2261 .
16.
Buter H , Hemmelder MH , Navis G , de Jong PE , de Zeeuw D.The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide . Nephrology Dialysis Transplantation1998; 13: 1682-1685 .
17.
Bakris GL , Weir MR.Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine - is this a cause for concern?Archives of Internal Medicine2000; 160: 685-693 .
18.
Ruggenenti P , Mise N , Pisoni Ret al.Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies . Circulation2003; 107: 586-592 .
19.
Houssiau FA , Vasconcelos C , D’Cruz Det al.Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from the long-term follow-up of the Euro-Lupus Nephritis Trial . Arthritis Rheum; in press.
20.
Bessant R , Hingorani A , Patel Let al.Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus . Rheumatology2004; 43: 924-929 .
21.
Mancia G , Rosei EA , Cifkova Ret al.2003 European society of hypertension - European Society of Cardiology guidelines for the management of arterial hypertension . Journal of Hypertension2003; 21: 1011-1053 .
22.
Chobanian AV , Bakris GL , Black HRet al.Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure . Hypertension2003; 42: 1206-1252 .
23.
Levey AS.Nondiabetic kidney disease . New England Journal of Medicine2002; 347: 1505-1511 .
24.
Bakris GL , Weir MR , Secic M , Campbell B , Weis-McNulty A.Differential effects of calcium antagonist subclasses on markers of nephropathy progression . Kidney International2004; 65: 1991-2002 .
25.
Locatelli F , Del Vecchio L.How long can dialysis be postponed by low protein diet and ACE inhibitors?Nephrology Dialysis Transplantation1999; 14: 1360-1364 .
26.
Wilmer WA , Rovin BH , Hebert CJet al.Management of glomerular proteinuria: a commentary . Journal of the American Society of Nephrology2003; 14: 3217-3232 .
27.
Klahr S , Levey AS , Beck GJet al.The effects of dietary-protein restriction and blood-pressure control on the progression of chronic renal-disease . New England Journal of Medicine1994; 330: 877-884 .
28.
Roman MJ , Shanker B , Davis Aet al.Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus . New England Journal of Medicine2003; 349: 2399-2406 .
29.
Asanuma Y , Oeser A , Shintani AKet al.Premature coronary-artery atherosclerosis in systemic lupus erythematosus . New England Journal of Medicine2003; 349: 2407-2415 .
30.
Smith CR.Lipid-lowering therapy - new and established agents reduce risk of cardiovascular events . Postgraduate Medicine2004; 115: 29-36 .
31.
McCarey DW , McInnes LB , Madhok Ret al.Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial . Lancet2004; 363: 2015-2021 .
32.
Hahn BH.Systemic lupus erythematosus and accelerated atherosclerosis . New England Journal of Medicine2003; 349: 2379-2380 .
33.
Devuyst O , Goffin E , Pirson Y , Destrihou CV.Creatinine rise after fibrate therapy in renal graft recipients . Lancet1993; 341: 840-840 .
34.
Martinez-Berriotxoa A , Ruiz-Irastorza G , Arberas MVE , Gutierrez MR , Errasti CA.Plasma homocysteine levels in systemic lupus erythematosus . Medicina Clinica2003; 120: 681-685 .
35.
De Vriese AS , Verbeke F , Schrijvers BF , Lameire NH.Is folate a promising agent in the prevention and treatment of cardiovascular disease in patients with renal failure?Kidney International2002; 61: 1199-1209 .
36.
Lange H , Suryapranata H , De Luca Get al.Folate therapy and in-stent restenosis after coronary stenting . New England Journal of Medicine2004; 350: 2673-2681 .
37.
Ohlenschlaeger T , Garred P , Madsen HO , Jacobsen S.Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus . New England Journal of Medicine2004; 351: 260-267 .
38.
Ifudu O , Dawood M , Homel P , Friedman EA.Excess morbidity in patients starting uremia therapy without prior care by a nephrologist . American Journal of Kidney Diseases1996; 28: 841-845 .
39.
Jungers P , Zingraff J , Albouze Get al.Late referral to maintenance dialysis - detrimental consequences . Nephrology Dialysis Transplantation1993; 8: 1089-1093 .
40.
Kinchen KS , Sadler J , Fink Net al.The timing of specialist evaluation in chronic kidney disease and mortality . Annals of Internal Medicine2002; 137: 479-486 .
41.
Locatelli F , Aljama PA , Barany Pet al.Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure . Nephrology Dialysis Transplantation2004; 19: 1-47 .
42.
Eknoyan G , Levin A , Levin NW.Bone metabolism and disease in chronic kidney disease . Am J Kidney Dis2003; 42(suppl. 3): S1-S201 .
